About: L-Carnitine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: L-Carnitine Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4E76-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4E77-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4E72-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4E73-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4E74-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4E75-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Olpin SE: Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab. 2005;51(5-6):289-306. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15991803 # Steiber A, Kerner J, Hoppel CL: Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004 Oct-Dec;25(5-6):455-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15363636 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	17.4 hours (elimination) following a single intravenous dose. (en)
http://linked.open...ugbank/indication	For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease. (en)
http://linked.open...bank/manufacturer	Sigma tau pharmaceuticals inc United Research Laboratories Inc. Luitpold pharmaceuticals inc Abbott laboratories pharmaceutical products div Pfizer Inc. Lyne laboratories inc Bedford laboratories
sameAs	L-Carnitine
Title	L-Carnitine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/chebi/16347 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/chemspider/10455 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/drugbank/DB00583 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/kegg-compound/C00318 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/kegg-drug/D02176 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/national-drug-code-directory/0517-1055-25 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pubchem-compound/10917 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pubchem-substance/46505864 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pharmgkb/PA450154 http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/wikipedia/L-Carnitine
http://linked.open...mechanismOfAction	Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases. (en)
http://linked.open...drugbank/packager	Northstar healthcare holdings ltd Par pharmaceutical inc Purepac pharmaceutical co Sandoz inc
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6335369
http://linked.open...outeOfElimination	Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval. Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days. (en)
http://linked.open.../drugbank/synonym	L-Carnitine (en) Carnitor (en) Karnitin (en) (-)-Carnitine (en) (-)-L-Carnitin (en) (S)-Carnitine (en) Carnitine (en) 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium (en) (-)-L-Carnitine (en) (R)-Carnitine (en) Carnicor (en) Carnitene (en) Levocarnitin (en) Levocarnitina (en) Levocarnitinum (en) Lévocarnitine (en) Vitamin bt (en) 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt (en)
http://linked.open...drugbank/toxicity	LD<sub>50</sub> > 8g/kg (mouse, oral). Adverse effects include hypertension, fever, tachycardia and seizures. (en)
http://linked.open...umeOfDistribution	The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/40-20-00
http://linked.open.../drugbank/mixture	Car-Q Food Nutrition Inc. Men's Vitamin and Mineral Supplement Evion-LC
http://linked.open...nk/proteinBinding	None (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Noguchi, J. and Sakota, N.; US. Patent 3,135,788; June 2,1964; assigned to Nihon Zoki Seiyaku Kabushikikaisha (Japan). (en)
foaf:page	http://www.rxlist.com/cgi/generic3/carnitor.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4E7C-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4E82-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4E81-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4E7E-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4E7F-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4E80-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4E7A-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4E92-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4E78-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4E7B-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4E79-363D-11E5-9242-09173F13E4C5
http://linked.open...logy/drugbank/pKa	http://linked.opendata.cz/resource/drugbank/property/271B4E94-363D-11E5-9242-09173F13E4C5
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4E88-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4E89-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4E83-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4E84-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4E86-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4E85-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4E87-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	541-15-1 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Total body clearance was found to be a mean of 4L/h. (en)
http://linked.open...gbank/containedIn	L-carnitine powder Carnitor 1 gm/5 ml vial Allopurinol powder Apo-Allopurinol 100 mg Tablet Allopurinol sodium 500 mg vial Aloprim 500 mg vial Cyklokapron 100 mg/ml ampul
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4E8E-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4E90-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4E91-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software